Literature DB >> 15316087

Effect of novel alpha-conotoxins on nicotine-stimulated [3H]dopamine release from rat striatal synaptosomes.

Layla Azam1, J Michael McIntosh.   

Abstract

Nicotine's action on the midbrain dopaminergic neurons is mediated by nicotinic acetylcholine receptors (nAChRs) that are present on the cell bodies and the terminals of these neurons. Previously, it was suggested that one of the nAChR subtypes located on striatal dopaminergic terminals may be an alpha3beta2 subtype, based on partial inhibition of nicotine-stimulated [(3)H]dopamine release by alpha-conotoxin MII, a potent inhibitor of heterologously expressed alpha3beta2 nAChRs. More recent studies indicated that alpha-conotoxin MII also potently blocks alpha6-containing nAChRs. In the present study, we have examined the nAChR subtype(s) modulating [(3)H]dopamine release from striatal terminals by using novel alpha-conotoxins that have 37- to 78-fold higher selectivity for alpha6-versus alpha3-containing nAChRs. All of the peptides partially (20-35%) inhibit nicotine-stimulated [(3)H]dopamine release with IC(50) values consistent with those obtained with heterologously expressed rat alpha6-containing nicotinic acetylcholine receptors. These results, together with previous studies by others, further support the idea that alpha6-containing nicotinic receptors modulate nicotine-stimulated dopamine release from rat striatal synaptosomes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15316087     DOI: 10.1124/jpet.104.071456

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  23 in total

1.  Amino acid residues that confer high selectivity of the alpha6 nicotinic acetylcholine receptor subunit to alpha-conotoxin MII[S4A,E11A,L15A].

Authors:  Layla Azam; Doju Yoshikami; J Michael McIntosh
Journal:  J Biol Chem       Date:  2008-02-25       Impact factor: 5.157

Review 2.  Mysterious alpha6-containing nAChRs: function, pharmacology, and pathophysiology.

Authors:  Ke-chun Yang; Guo-zhang Jin; Jie Wu
Journal:  Acta Pharmacol Sin       Date:  2009-06       Impact factor: 6.150

3.  Positional scanning mutagenesis of α-conotoxin PeIA identifies critical residues that confer potency and selectivity for α6/α3β2β3 and α3β2 nicotinic acetylcholine receptors.

Authors:  Arik J Hone; Miguel Ruiz; Mick'l Scadden; Sean Christensen; Joanna Gajewiak; Layla Azam; J Michael McIntosh
Journal:  J Biol Chem       Date:  2013-07-11       Impact factor: 5.157

4.  Indolizidine (-)-235B' and related structural analogs: discovery of nicotinic receptor antagonists that inhibit nicotine-evoked [3H]dopamine release.

Authors:  Marharyta Pivavarchyk; Andrew M Smith; Zhenfa Zhang; Dejun Zhou; Xu Wang; Naoki Toyooka; Hiroshi Tsuneki; Toshiyasu Sasaoka; J Michael McIntosh; Peter A Crooks; Linda P Dwoskin
Journal:  Eur J Pharmacol       Date:  2011-03-01       Impact factor: 4.432

Review 5.  Progress and challenges in the study of α6-containing nicotinic acetylcholine receptors.

Authors:  Sharon R Letchworth; Paul Whiteaker
Journal:  Biochem Pharmacol       Date:  2011-06-28       Impact factor: 5.858

6.  Alpha6-containing nicotinic acetylcholine receptor is a highly sensitive target of alcohol.

Authors:  Fenfei Gao; Dejie Chen; Xiaokuang Ma; Sterling Sudweeks; Jordan T Yorgason; Ming Gao; Dharshaun Turner; Jason Brek Eaton; J Michael McIntosh; Ronald J Lukas; Paul Whiteaker; Yongchang Chang; Scott C Steffensen; Jie Wu
Journal:  Neuropharmacology       Date:  2019-01-30       Impact factor: 5.250

7.  Developmental regulation of nicotinic acetylcholine receptors within midbrain dopamine neurons.

Authors:  L Azam; Y Chen; F M Leslie
Journal:  Neuroscience       Date:  2006-12-29       Impact factor: 3.590

Review 8.  Alpha-conotoxins as pharmacological probes of nicotinic acetylcholine receptors.

Authors:  Layla Azam; J Michael McIntosh
Journal:  Acta Pharmacol Sin       Date:  2009-05-18       Impact factor: 6.150

9.  Structural basis for alpha-conotoxin potency and selectivity.

Authors:  Matt Turner; Seth Eidemiller; Bryan Martin; Andrew Narver; Joshua Marshall; Logan Zemp; Kenneth A Cornell; J Michael McIntosh; Owen M McDougal
Journal:  Bioorg Med Chem       Date:  2009-07-09       Impact factor: 3.641

10.  r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement.

Authors:  Joshua S Beckmann; Andrew C Meyer; M Pivavarchyk; David B Horton; Guangrong Zheng; Andrew M Smith; Thomas E Wooters; J Michael McIntosh; Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  Neurochem Res       Date:  2015-07-31       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.